Extraprostatic extension of gleason 6 prostate cancer: single center experience
Yıl: 2021 Cilt: 16 Sayı: 2 Sayfa Aralığı: 165 - 170 Metin Dili: İngilizce DOI: 10.33719/yud.2021;16-2-844173 İndeks Tarihi: 15-08-2022
Extraprostatic extension of gleason 6 prostate cancer: single center experience
Öz: Objective: For Gleason Score (GS) 3+3:6 prostate cancer (PC) cases, recent guidelines recommend clinical follow-up instead of radical treatment due to complications. One of the most important disadvantages of clinical follow-up is that low-grade PC may include local aggressive behavior. Hence, our aim here was to investigate the incidence of extraprostatic extension (EPE), a local aggressive behavior, in GS6 PC cases. Material and Methods: We examined 119 materials diagnosed with prostatic adenocarcino- ma (GS 3+3:6) with no tertiary pattern and that were sent to our department as radical prostatec- tomy materials between January 2010 – May 2019. We investigated how many of the materials had EPE. Results: We observed EPE in 16 (13.45%) of our cases. 5 of the cases had vesicula seminalis invasion (pT3b) and 11 had EPE and/or bladder neck invasion (pT3a) without vesicula seminalis invasion. Conclusion: Among our patients diagnosed with GS-6 PC, we observed EPE (pT3) in 13.45% and vesicula seminalis invasion (pT3b) in 4.2%, which suggests that the possibility of EPE is not uncommon in GS-6 PC. Based on these findings, we argue that patients with GS-6 PC under clin- ical follow-up should be followed more carefully for EPE.
Anahtar Kelime: Gleason skor 6 prostat kanserinin ekstraprostatik yayılımı: tek merkez deneyimi
Öz: Amaç: Son yıllarda tedavi komplikasyon- larından dolayı gleason skor (GS) 3+3:6 prostat kanserlerinde (PK) radikal tedavi yerine klinik izlem önerilmektedir. Radikal tedavi yerine klinik izlem uygulanmasının en önemli dezavantajların- dan biri düşük dereceli PK’ da lokal agresif dav- ranış görülebilmesidir. Çalışmamızda amacımız GS-6 PK’ da lokal agresif davranış olarak kabul edilen ekstraprostatik yayılım (EPY) görülme ora- nını araştırmaktır. Gereç ve Yöntemler: Çalışmamıza Ocak 2010-Mayıs 2019 yılları arasında bölümümüze ra- dikal prostatektomi materyali olarak gönderilmiş prostatik adenokarsinom (GS 3+3:6) tanısı almış tersiyer patern içermeyen 119 materyal incelendi. Bu materyallerden kaçında EPY olduğu araştırıldı. Bulgular: Çalışmamızda olguların 16 tane- sinde (%13,45) EPY tespit edildi. Bunlardan 5’ inde veziküla seminalis invazyonu (pT3b), 11’ inde vezikula seminalis invazyonu olmadan EPY ve/veya mesane boyun invazyonu (pT3a) izlendi. Sonuç: GS-6 PK tanısı alan olgularımızın %13,45’ inde EPY (pT3), %4,2’ sinde seminal vezi- kül invazyonu (pT3b) izlememizden dolayı GS-6 PK’ nın EPY yapma olasılığının nadir olmadığını düşünüyoruz. Bu bulgularımızdan yola çıkarak klinik izlem uygulanan GS-6 PK’ lı olguların EPY açısından daha dikkatli takip edilmesi gerektiğini savunuyoruz.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer in- cidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):359-386.
- 2. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The ep- idemiology of prostate cancer. Cold Spring Harb Per- spect Med. 2018; 8(12):a030361.
- 3. Yilmaz B, Sarikaya D. Prostat Kanseri İnsidansı ve Risk Faktörleri. Türkiye Klinikleri Tıbbi Onkoloji-Özel Konular 2017; 10:337-342.
- 4. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 3.2012 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network 2012; 10:1081-1087.
- 5. Rubio-Briones J, Borque A, Esteban L, et al. Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer. Actas Urol Esp. 2016; 40(1):3-10.
- 6. Samaratunga H, Delahunt B, Egevad L, Srigley JR, Yax- ley J. The evolution of Gleason grading of prostate can- cer. J Diagn Pathol. 2017; 12:5-11.
- 7. Liu J-J, Lichtensztajn DY, Gomez SL, et al. Nationwide prevalence of lymph node metastases in Gleason score 3+ 3= 6 prostate cancer. Pathology. 2014; 46(2):306-310.
- 8. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2016; 40(2):244-252.
- 9. Mohler j, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. Prac- tice Guideline J Natl Compr Canc Netw. 2010; 8(2):162- 200.
- 10. Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011; 107(4):576-584.
- 11. Carter HB, Partin AW, Walsh PC, et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer? Journal of Clinical Oncology 2012;30(35):4294.
- 12. Hernandez DJ, Nielsen ME, Han M, et al. Natural his- tory of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatecto- my. Urology. 2008; 72:172-176.
- 13. Anderson BB, Oberlin DT, Razmaria AA et al. Extrapros- tatic extension is extremely rare for contemporary Glea- son score 6 prostate cancer. Eur Urol. 2017; 72:455-460.
- 14. Hassan O, Han M, Zhou A, et al. Incidence of extrapros- tatic extension at radical prostatectomy with pure Glea- son score 3+ 3= 6 (grade group 1) cancer: Implications for whether Gleason score 6 prostate cancer should be renamed” not cancer” and for selection criteria for active surveillance. J Urol. 2018; 199:1482-1487.
- 15. Takamatsu K, Matsumoto K, Shojo K, et al. The prog- nostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after rad- ical prostatectomy. Urologic Oncology: Seminars and Original Investigations; 2019; 37(9):19-25.
- 16. Farchoukh L, Laframboise WA, Nelson JB, Bastacky S, Parwani AV, Dhir R. Multifocal Extraprostatic Exten- sion of Prostate Cancer: A Third Subtype With Worse Prognosis Than Focal Prostate Cancer. Am J Clin Pathol. 2020; 153:548-553.
- 17. Maubon T, Branger N, Bastide C, et al. Impact of the extent of extraprostatic extension defined by Epstein’s method in patients with negative surgical margins and negative lymph node invasion. Prostate Cancer Prostat- ic Dis. 2016; 19:317-321.
- 18. Ball MW, Partin AW, Epstein JI. Extent of extraprostatic extension independently influences biochemical recur- rence-free survival: evidence for further pT3 subclassi- fication. Urology. 2015; 85:161-164.
| APA | Ceylan O, Demirtaş R (2021). Extraprostatic extension of gleason 6 prostate cancer: single center experience. , 165 - 170. 10.33719/yud.2021;16-2-844173 |
| Chicago | Ceylan Onur,Demirtaş Rabia Extraprostatic extension of gleason 6 prostate cancer: single center experience. (2021): 165 - 170. 10.33719/yud.2021;16-2-844173 |
| MLA | Ceylan Onur,Demirtaş Rabia Extraprostatic extension of gleason 6 prostate cancer: single center experience. , 2021, ss.165 - 170. 10.33719/yud.2021;16-2-844173 |
| AMA | Ceylan O,Demirtaş R Extraprostatic extension of gleason 6 prostate cancer: single center experience. . 2021; 165 - 170. 10.33719/yud.2021;16-2-844173 |
| Vancouver | Ceylan O,Demirtaş R Extraprostatic extension of gleason 6 prostate cancer: single center experience. . 2021; 165 - 170. 10.33719/yud.2021;16-2-844173 |
| IEEE | Ceylan O,Demirtaş R "Extraprostatic extension of gleason 6 prostate cancer: single center experience." , ss.165 - 170, 2021. 10.33719/yud.2021;16-2-844173 |
| ISNAD | Ceylan, Onur - Demirtaş, Rabia. "Extraprostatic extension of gleason 6 prostate cancer: single center experience". (2021), 165-170. https://doi.org/10.33719/yud.2021;16-2-844173 |
| APA | Ceylan O, Demirtaş R (2021). Extraprostatic extension of gleason 6 prostate cancer: single center experience. Yeni Üroloji Dergisi, 16(2), 165 - 170. 10.33719/yud.2021;16-2-844173 |
| Chicago | Ceylan Onur,Demirtaş Rabia Extraprostatic extension of gleason 6 prostate cancer: single center experience. Yeni Üroloji Dergisi 16, no.2 (2021): 165 - 170. 10.33719/yud.2021;16-2-844173 |
| MLA | Ceylan Onur,Demirtaş Rabia Extraprostatic extension of gleason 6 prostate cancer: single center experience. Yeni Üroloji Dergisi, vol.16, no.2, 2021, ss.165 - 170. 10.33719/yud.2021;16-2-844173 |
| AMA | Ceylan O,Demirtaş R Extraprostatic extension of gleason 6 prostate cancer: single center experience. Yeni Üroloji Dergisi. 2021; 16(2): 165 - 170. 10.33719/yud.2021;16-2-844173 |
| Vancouver | Ceylan O,Demirtaş R Extraprostatic extension of gleason 6 prostate cancer: single center experience. Yeni Üroloji Dergisi. 2021; 16(2): 165 - 170. 10.33719/yud.2021;16-2-844173 |
| IEEE | Ceylan O,Demirtaş R "Extraprostatic extension of gleason 6 prostate cancer: single center experience." Yeni Üroloji Dergisi, 16, ss.165 - 170, 2021. 10.33719/yud.2021;16-2-844173 |
| ISNAD | Ceylan, Onur - Demirtaş, Rabia. "Extraprostatic extension of gleason 6 prostate cancer: single center experience". Yeni Üroloji Dergisi 16/2 (2021), 165-170. https://doi.org/10.33719/yud.2021;16-2-844173 |
